Current portfolio

• Allcyte (acq. Exscientia). Precision oncology (Austria);
• Anagenex. DNA-encoded libraries (USA);
• ClipDrop. AI-first photos (France);
• Exscientia (NASDAQ: EXAI). Patient-first AI (UK);
• Gourmey. Cell-based meat (France);
• Graphcore. Semiconductors for AI (UK);
• Intenseye. Workplace safety (Turkey);
• LabGenius. Protein therapeutics (UK);
• Mission Barns. Lab-grown fat (USA);
• Unannounced. One AI for defense (USA);
• Unannounced. Structural biology for drug design (Canada);
• Unannounced. Reinventing robotics (UK/USA);
• Unannounced. Liquid biopsies for cancer care (FI/CH);
• Unannounced. See the future in cells (UK);
• Valence Discovery. AI-first drug design (Canada);
• V7. Computer vision data platform (UK);
• ZOE. Eat what's good for you (UK);

Previous investments

• Andela. Remote engineering teams (USA);
• Jukedeck (acq. ByteDance). AI-first music (UK);
• Mapillary (acq. Facebook). Make better maps (Sweden);
• Numerai. The world's open hedge fund (USA);
• Optimal. Autonomous indoor farms (UK);
• PolyAI. Enterprise-ready voice assistants (UK);
• Ravelin. Helping online businesses grow securely (UK);
• Recursion (NASDAQ: RXRX). Decode biology to radically improve lives (USA);
• The Engineering Company. Engineering development platform (UK);
• Thought Machine. Cloud native core banking (UK);
• Tractable. AI for accident and disaster recovery (UK);
• Starship. Self-driving delivery robots (Estonia);
• Stripe. Payments infrastructure for the internet (USA);